Representative Val T. Hoyle (D-Oregon) recently sold shares of Merck & Co., Inc. (NYSE:MRK). In a filing disclosed on October 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Merck & Co., Inc. stock on September 23rd. The trade occurred in the Representative’s “FIDELITY ROLLOVER IRA” account.
Representative Val T. Hoyle also recently made the following trade(s):
- Sold $1,001 – $15,000 in shares of Marriott International (NASDAQ:MAR) on 9/23/2025.
- Sold $1,001 – $15,000 in shares of Transdigm Group (NYSE:TDG) on 9/23/2025.
- Sold $1,001 – $15,000 in shares of H&R Block (NYSE:HRB) on 9/23/2025.
- Sold $1,001 – $15,000 in shares of NIKE (NYSE:NKE) on 9/23/2025.
- Sold $1,001 – $15,000 in shares of Bank of New York Mellon (NYSE:BK) on 9/23/2025.
- Sold $1,001 – $15,000 in shares of Cisco Systems (NASDAQ:CSCO) on 9/23/2025.
- Sold $1,001 – $15,000 in shares of Capital One Financial (NYSE:COF) on 9/23/2025.
- Sold $1,001 – $15,000 in shares of Pentair (NYSE:PNR) on 9/23/2025.
- Sold $1,001 – $15,000 in shares of Heico (NYSE:HEI.A) on 9/23/2025.
- Sold $1,001 – $15,000 in shares of Target (NYSE:TGT) on 9/23/2025.
Merck & Co., Inc. Price Performance
Shares of NYSE MRK opened at $86.02 on Friday. The firm has a market capitalization of $214.87 billion, a P/E ratio of 13.25, a P/E/G ratio of 0.88 and a beta of 0.37. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69. The stock’s 50-day simple moving average is $83.47 and its two-hundred day simple moving average is $81.47. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $111.58.
Merck & Co., Inc. Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th were paid a $0.81 dividend. This represents a $3.24 dividend on an annualized basis and a yield of 3.8%. The ex-dividend date was Monday, September 15th. Merck & Co., Inc.’s dividend payout ratio is currently 49.92%.
Institutional Investors Weigh In On Merck & Co., Inc.
Institutional investors have recently bought and sold shares of the stock. Legend Financial Advisors Inc. purchased a new stake in Merck & Co., Inc. during the 2nd quarter valued at about $25,000. Barnes Dennig Private Wealth Management LLC purchased a new stake in Merck & Co., Inc. during the 1st quarter valued at about $27,000. Kilter Group LLC purchased a new stake in Merck & Co., Inc. during the 2nd quarter valued at about $27,000. Bare Financial Services Inc boosted its holdings in Merck & Co., Inc. by 51.9% during the 2nd quarter. Bare Financial Services Inc now owns 366 shares of the company’s stock valued at $29,000 after acquiring an additional 125 shares during the period. Finally, Evolution Wealth Management Inc. purchased a new stake in Merck & Co., Inc. during the 2nd quarter valued at about $31,000. 76.07% of the stock is currently owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several equities analysts have recently commented on MRK shares. Berenberg Bank lowered Merck & Co., Inc. from a “buy” rating to a “hold” rating and reduced their price objective for the company from $100.00 to $90.00 in a research report on Wednesday, September 17th. Morgan Stanley reduced their price objective on Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating on the stock in a research report on Thursday, July 10th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Merck & Co., Inc. in a research report on Wednesday. Finally, Wells Fargo & Company reduced their price objective on Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating on the stock in a research report on Wednesday, July 30th. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, fourteen have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $104.31.
View Our Latest Stock Report on Merck & Co., Inc.
About Representative Hoyle
Val Hoyle (Democratic Party) is a member of the U.S. House, representing Oregon’s 4th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.
Hoyle (Democratic Party) is running for re-election to the U.S. House to represent Oregon’s 4th Congressional District. She declared candidacy for the 2026 election.
Val Hoyle was born in California and lives in Springfield, Oregon. Hoyle graduated from Merrimack High School. She earned a B.A. in political science from Emmanuel College in 1992. Her career experience includes working as a director at United Way of Lane County, a policy fellow at Wayne Morse Center for Law and Politics, and a commissioner at the Oregon Bureau of Labor and Industries. Hoyle has also worked in domestic and international sales, as well as manufacturing distribution.
Merck & Co., Inc. Company Profile
Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
Further Reading
- Five stocks we like better than Merck & Co., Inc.
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Bassett Furniture: Buy Now, Sit Back, and Collect Dividends
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- AST SpaceMobile’s Big Win: Shares Soar on New Deal With Verizon
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Catch the Next Bitcoin Rally With These 3 ETFs
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.